Troy O. Harasym
- Molecular Biology top 5%
- Biomaterials top 1%
- Biomedical Engineering top 5%
- Hematology top 5%
- Oncology top 10%
- Co-authors
- Lawrence D. MayerPaul TardiMarcel B. BallySharon A. JohnstoneSteven M. AnsellNatashia HarasymSean C. SempleSandra K. Klimuk
- Topics
- Nanoparticle-Based Drug Delivery (23 papers)Hepatitis B Virus Studies (10 papers)RNA Interference and Gene Delivery (9 papers)
- Partner nations
- CanadaUnited StatesAustralia
In The Last Decade
Troy O. Harasym
44 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 93
- Molecular Biology 1.3k
- Biomaterials 915
- Biomedical Engineering 483
- Hematology 339
- Oncology 306
Countries citing papers authored by Troy O. Harasym
This map shows the geographic impact of Troy O. Harasym's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Troy O. Harasym with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Troy O. Harasym more than expected).
Fields of papers citing papers by Troy O. Harasym
This network shows the impact of papers produced by Troy O. Harasym. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Troy O. Harasym. The network helps show where Troy O. Harasym may publish in the future.
Co-authorship network of co-authors of Troy O. Harasym
This figure shows the co-authorship network connecting the top 25 collaborators of Troy O. Harasym. A scholar is included among the top collaborators of Troy O. Harasym based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Troy O. Harasym. Troy O. Harasym is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 4 | |
| 3 | 5 | |
| 4 | 6 | |
| 5 | 8 | |
| 6 | 64 | |
| 7 | 118 | |
| 8 | 26 | |
| 9 | 98 | |
| 10 | 28 | |
| 11 | Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications | 3 |
| 12 | 288 | |
| 13 | 29 | |
| 14 | Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models | 3 |
| 15 | 167 | |
| 16 | A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer | 2 |
| 17 | 32 | |
| 18 | 379 | |
| 19 | 37 | |
| 20 | 54 |
About Troy O. Harasym
Troy O. Harasym is a scholar working on Biomaterials, Hepatology and Pharmaceutical Science, having authored 45 papers that have together received 2.2k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (23 papers), Hepatitis B Virus Studies (10 papers) and RNA Interference and Gene Delivery (9 papers). The work is most often cited by research in Biomaterials (915 citations), Hematology (339 citations) and Pharmaceutical Science (119 citations). Troy O. Harasym has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include Lawrence D. Mayer, Paul Tardi, Marcel B. Bally, Sharon A. Johnstone, Steven M. Ansell, Natashia Harasym, Sean C. Semple, Sandra K. Klimuk, Michael J. Hope and David Bermudes. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.